1Nabel GJ . Mapping the future of HIV vaccines [J] . Nature review microbiology, 2007,5 : 482-484.
2Gallo RC, Satin PS,Gelmann EP,et al . Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)[J] . Science 1983,220 : 865-867.
3Barin F,M Boup S,Denis F,et al . Serological evidence for virus related to simian T-lymphotropie retrovirus IU in residents of west Africa[J]. Lancet 1985,2 : 1387-1389.
4Eckert D M,Kim P S. Design of potent inhibitors of HIV-1 entry from the gp41.N-Petide region[J]. Proc Natl Acad Sci USA,2001,98 (2):11187-11192.
5Cormier E G,Tran D N H,Sanders R W,et al . Mapping the determinants of CCRs animo-terminal sulfopeptide interaction with soluble human immunodeficiency virus typet gp120-CD4 complex[J]. J virol,2001,25(1 ):5541-5549.
6Gaywee J,Artenstein AW, VanCott TC, et al . Correlation of genetic and serologic approaches to HIV-Ⅰ sub typing in Thailand [J] . J Acquir Immune Defic Syndr Hum Retrovirol 1996,13 : 392-396.
7Tomkowicz B, CoUman R G. HIV-1 entry inhibitors:closing the front door[J]. Expertpin Ther Targets,2006,8(2) :65-78.
8Men4ndez-Arias I . Targeting HIV:antiretroviral therapy and development of drug resistance [J] . Trends Pharmaeol Sci,2002,23 (8):381-388.
9Opar A . New HIV drug classes on the horizon [J] . Nat Rev Drug Discov,2007,6(4) : 258-259.
10Li F,Goila--Gaur R,Salzwedel K,et al . PA-457:a potent HIV inhibitor that disrupts eore condensation by targeting a late step in Gag processing [J] . Proc Natl Acad Sci USA,2003,100 (23): 13555-13560.
